Explore / Peer-reviewed article
Peer-reviewed article

The potential of psychedelic medicine - A personal account.

Smith DE

Journal of the neurological sciencesJan 3, 2022United States0 citationsDOI: 10.1016/j.jns.2021.120128

Abstract

In 1965, I was training in clinical toxicology in the pharmacology department of the University of California San Francisco (UCSF) and living in the Haight Ashbury. I studied various psychedelics, including LSD, mescaline, and ibogaine, in human and animal models. The psychedelics were then being used as a therapeutic drug in clinical settings and researched as a potential antipersonnel agent by the U.S. government. Then, using psychedelics became a rite of passage for the emerging countercultural movement. After adverse reactions and negative publicity, states began to criminalize these drugs, beginning in 1966. The federal government eventually moved these drugs to Schedule 1 classification, shutting down research almost entirely.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

LSDIbogaineMescalineAddiction

Keywords

RecoveryPsychedelicsEntactogensEntheogensHaight Ashbury Free Clinic

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.